EP300 and idiopathic pulmonary fibrosis: Inactivation of EP300 in vitro (patient-derived primary fibroblast), in vivo (bleomycin mouse model) and ex vivo (precision-cut lung slices, PCLS) IPF models causes reduction of fibrotic hallmarks, making EP300 inhibition a novel potential therapy against IPF.